<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: of the VAC ", fill: "#8b008b"},
{source: "3: of the VAC ", target: "3: competitors", fill: "#8b008b"},
{source: "3: competitors", target: "3: introduced products", fill: "#8b008b"},
{source: "3: of the VAC ", target: "6: dressings which", fill: "#f6adc6"},
{source: "6: dressings which", target: "6: recently been assigned by", fill: "#f6adc6"},
{source: "6: recently been assigned by", target: "6: Centers for Medicare ", fill: "#f6adc6"},
{source: "6: Centers for Medicare ", target: "6: Medicaid Services CMS ", fill: "#f6adc6"},
{source: "6: Medicaid Services CMS ", target: "6: reimbursement codes", fill: "#f6adc6"},
{source: "6: reimbursement codes", target: "6: disposables", fill: "#f6adc6"},
{source: "6: dressings which", target: "10: competitors", fill: "#f6c"},
{source: "10: competitors", target: "10: thirdparty reimbursement", fill: "#f6c"},
{source: "10: thirdparty reimbursement", target: "10: competing products", fill: "#f6c"},
{source: "10: competing products", target: "10: care market could substantially erode", fill: "#f6c"},
{source: "10: care market could substantially erode", target: "10: systems could", fill: "#f6c"},
{source: "10: systems could", target: "10: decline significantly either", fill: "#f6c"},
{source: "10: decline significantly either", target: "10: which could materially", fill: "#f6c"},
{source: "10: which could materially", target: "10: adversely affect", fill: "#f6c"},
{source: "10: competitors", target: "14: competitors", fill: "#d10056"},
{source: "14: competitors", target: "14: markets may", fill: "#d10056"},
{source: "14: markets may", target: "14: products less desirable", fill: "#d10056"},
{source: "14: products less desirable", target: "14: competitors may effectively limit", fill: "#d10056"},
{source: "14: competitors may effectively limit", target: "14: market access", fill: "#d10056"},
{source: "14: market access", target: "14: through sole source contracts with", fill: "#d10056"},
{source: "14: through sole source contracts with", target: "14: health care providers", fill: "#d10056"},
{source: "14: competitors", target: "52: thirdparty", fill: "#f5deb3"},
{source: "52: thirdparty", target: "52: reimbursement", fill: "#f5deb3"},
{source: "52: reimbursement", target: "52: adversely affect", fill: "#f5deb3"},
{source: "52: thirdparty", target: "126: manufacturing", fill: "#21abcd"},
{source: "126: manufacturing", target: "126: facilities", fill: "#21abcd"},
{source: "126: facilities", target: "126: disposables", fill: "#21abcd"},
{source: "126: disposables", target: "126: different locations", fill: "#21abcd"},
{source: "126: different locations", target: "126: supply interruptions from", fill: "#21abcd"},
{source: "126: supply interruptions from", target: "126: for the Avail ", fill: "#21abcd"},
{source: "126: for the Avail ", target: "126: manufacturing facility", fill: "#21abcd"},
{source: "126: manufacturing", target: "161: consequences", fill: "#ffc40c"},
{source: "161: consequences", target: "161: difficult", fill: "#ffc40c"},
{source: "161: difficult", target: "161: obligations under", fill: "#ffc40c"},
{source: "161: obligations under", target: "161: facility", fill: "#ffc40c"},
{source: "161: facility", target: "161: senior subordinated", fill: "#ffc40c"},
{source: "161: senior subordinated", target: "161: default on", fill: "#ffc40c"},
{source: "161: default on", target: "161: secured debt", fill: "#ffc40c"},
{source: "161: secured debt", target: "161: lenders may foreclose on", fill: "#ffc40c"},
{source: "161: lenders may foreclose on", target: "161: significant", fill: "#ffc40c"},
{source: "161: significant", target: "161: cash flow", fill: "#ffc40c"},
{source: "161: cash flow", target: "161: scheduled debt service rather than", fill: "#ffc40c"},
{source: "161: scheduled debt service rather than", target: "161: operations", fill: "#ffc40c"},
{source: "161: operations", target: "161: equity financing", fill: "#ffc40c"},
{source: "161: equity financing", target: "161: opportunities", fill: "#ffc40c"},
{source: "161: opportunities", target: "161: acquisitions", fill: "#ffc40c"},
{source: "161: acquisitions", target: "161: divestitures", fill: "#ffc40c"},
{source: "161: divestitures", target: "161: vulnerability", fill: "#ffc40c"},
{source: "161: vulnerability", target: "161: general adverse economic", fill: "#ffc40c"},
{source: "161: general adverse economic", target: "161: conditions could", fill: "#ffc40c"},
{source: "161: conditions could", target: "161: competitive disadvantage compared", fill: "#ffc40c"},
{source: "161: competitive disadvantage compared", target: "161: competitors with less debt", fill: "#ffc40c"},
{source: "161: consequences", target: "START_HERE", fill: "#ffc40c"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Department Stores</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business_mileage_reimbursement_rate">Business mileage reimbursement rate</a></td>
      <td>The business mileage reimbursement rate is an optional standard mileage rate used in the United States for purposes of computing the allowable business deduction, for Federal income tax purposes under the Internal Revenue Code, at 26 U.S.C. § 162, for the business use of a vehicle. Under the law, the taxpayer for each year is generally entitled to deduct either the actual expense amount, or an amount computed using the standard mileage rate, whichever is greater.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Diagnosis-related_group">Diagnosis-related group</a></td>
      <td>Diagnosis-related group (DRG) is a system to classify hospital cases into one of originally 467 groups, with the last group (coded as 470 through v24, 999 thereafter) being "Ungroupable". This system of classification was developed as a collaborative project by Robert B Fetter, PhD, of the Yale School of Management, and John D. Thompson, MPH, of the Yale School of Public Health.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Disposable_product">Disposable product</a></td>
      <td>A disposable (also called disposable product) is a product designed for a single use after which it is recycled or is disposed as solid waste. The term is also sometimes used for products that may last several months (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Disposability">Disposability</a></td>
      <td>Disposability is the fifth album by Steve Lacy and was released on the Italian RCA label in 1966 featuring three tunes written by Thelonious Monk, one by Cecil Taylor, one by Carla Bley and four by Lacy performed by Lacy, Aldo Romano and Kent Carter.\n\n\n== Reception ==\nThe Allmusic review awarded the album 4 stars.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Disposable_tableware">Disposable tableware</a></td>
      <td>Disposable tableware includes all disposable tableware like \n\ndisposable cups made of paper, plastic, coated paper,\nplates\ntablecloths,\nplacemats\nplastic cutlery,\npaper napkins, etc.These products are prevalent in fast food restaurants, takeaways, but also for airline meals. In private settings, this kind of disposable products has proven very popular with consumers who prefer easy and quick cleanup after parties, etc.The marketing for disposable tableware is huge, with an estimated $7.5 billion in 2012 in the US alone.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Disposable_and_discretionary_income">Disposable and discretionary income</a></td>
      <td>Disposable income is total personal income minus current income taxes. In national accounts definitions, personal income minus personal current taxes equals disposable personal income.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gillette">Gillette</a></td>
      <td>Gillette is an American brand of safety razors and other personal care products including shaving supplies, owned by the multi-national corporation Procter &amp; Gamble (P&amp;G).\nBased in Boston, Massachusetts, United States, it was owned by The Gillette Company, a supplier of products under various brands until that company merged into P&amp;G in 2005.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Master_of_Puppets">Master of Puppets</a></td>
      <td>Master of Puppets is the third studio album by the American heavy metal band Metallica, released on March 3, 1986, by Elektra Records. Recorded in Denmark at Sweet Silence Studios with producer Flemming Rasmussen, it was the band's last album to feature bassist Cliff Burton, who died in a bus accident in Sweden during the album's promotional tour.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Misophonia">Misophonia</a></td>
      <td>Misophonia is a disorder of decreased tolerance to specific sounds or their associated stimuli that has been characterized using different language and methodologies. Reactions to trigger sounds range from anger and annoyance to activating a fight-or-flight response.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Comparison_of_DNS_blacklists">Comparison of DNS blacklists</a></td>
      <td>The following table lists technical information for assumed reputable DNS blacklists used for blocking spam.\n\n\n== Notes ==\n"Collateral listings"—Deliberately listing non-offending IP addresses, in order to coerce ISPs to take action against spammers under their control.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Complication_(medicine)">Complication (medicine)</a></td>
      <td>A complication in medicine, or medical complication, is an unfavorable result of a disease, health condition, or treatment. Complications may adversely affect the prognosis, or outcome, of a disease.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Anthropogenic_hazard">Anthropogenic hazard</a></td>
      <td>Anthropogenic hazards are hazards caused by human action or inaction. They are contrasted with natural hazards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Reproductive_toxicity">Reproductive toxicity</a></td>
      <td>Reproductive toxicity refers to the potential risk from a given chemical, physical or biologic agent to adversely affect  both male and female fertility as well as offspring development. Reproductive toxicants may adversely affect sexual function, ovarian failure, fertility  as well as causing developmental toxicity in the offspring.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Disparate_impact">Disparate impact</a></td>
      <td>Disparate impact in United States labor law refers to practices in employment, housing, and other areas that adversely affect one group of people of a protected characteristic more than another, even though rules applied by employers or landlords are formally neutral. Although the protected classes vary by statute, most federal civil rights laws protect based on race, color, religion, national origin, and sex as protected traits, and some laws include disability status and other traits as well.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Good_Environmental_Status">Good Environmental Status</a></td>
      <td>Good Environmental Status is a qualitative description of the state of the seas that the European Union's Marine Strategy Framework Directive requires its Member States to achieve or maintain by the year 2020. \nGood Environmental Status is described by 11 Descriptors:\n\nDescriptor 1.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Terrorist_and_Disruptive_Activities_(Prevention)_Act">Terrorist and Disruptive Activities (Prevention) Act</a></td>
      <td>Terrorist and Disruptive Activities (Prevention) Act, commonly known as TADA, was an Indian anti-terrorism law which was in force between 1985 and 1995 (modified in 1987) under the background of  the Punjab insurgency and was applied to whole of India. It was originally assented to by the President on 23 May 1985 and came into effect on 24 May 1985.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_global_issues">List of global issues</a></td>
      <td>A global issue is a matter of public concern worldwide. This list of global issues presents problems or phenomena affecting people around the world, including but not limited to widespread social issues, economic issues, and environmental issues.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Health_facility">Health facility</a></td>
      <td>A health facility is, in general, any location where healthcare is provided. Health facilities range from small clinics and doctor's offices to urgent care centers and large hospitals with elaborate emergency rooms and trauma centers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Reimbursement">Reimbursement</a></td>
      <td>Reimbursement is the act of compensating someone for an out-of-pocket expense by giving them an amount of money equal to what was spent.Companies, governments and nonprofit organizations may compensate their employees or officers for necessary and reasonable expenses; under US\nlaw, these expenses may be deducted from taxes by the organization and treated as untaxed income for the recipient provided that accountability conditions are met. UK law provides for deductions for travel and subsistence.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ERISA_reimbursement">ERISA reimbursement</a></td>
      <td>In the United States, ERISA reimbursement refers to the efforts of an ERISA Plan administrator (an insurer) to obtain repayment from an insured person who had previously received payments for personal injury medical bills.When an insurer pays a injury claim to someone, the insurer can seize cash settlements from whoever caused the injury. This “right of reimbursement” is essentially a subrogation claim.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Health_reimbursement_account">Health reimbursement account</a></td>
      <td>A Health Reimbursement Account, formally a Health Reimbursement Arrangement (HRA), is a type of US employer-funded health benefit plan that reimburses employees for out-of-pocket medical expenses and, in limited cases, to pay for health insurance plan premiums.An HRA is not truly an account, since it does not place funds under a separate legal title. Instead, it is an agreement under which the employee can submit qualified health expenses to the employer for reimbursement.Following implementation of the Affordable Care Act, HRAs must be integrated with a qualified employer-sponsored group health insurance plan to avoid excise tax penalties.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Capitation_(healthcare)">Capitation (healthcare)</a></td>
      <td>Capitation is a payment arrangement for health care service providers. It pays a set amount for each enrolled person assigned to them, per period of time, whether or not that person seeks care.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fee_Reimbursement_Scheme_(Andhra_Pradesh)">Fee Reimbursement Scheme (Andhra Pradesh)</a></td>
      <td>The Fee Reimbursement Scheme (also known as the Post-matric Scholarship Scheme) is a student education sponsorship programme of the Government of Andhra Pradesh. It supports students from lower economic strata in the state.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Certified_Medical_Reimbursement_Specialist">Certified Medical Reimbursement Specialist</a></td>
      <td>Certified Medical Reimbursement Specialist (CMRS) is a voluntary national credential that was created specifically for the medical billing professional. The American Medical Billing Association (AMBA) has been providing this industry certification and designation for nearly a decade.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Facility_management">Facility management</a></td>
      <td>Facility management, or facilities management, (FM) is a professional management discipline focused on the efficient and effective delivery of logistics and other support services related to real property, it encompasses multiple disciplines to ensure functionality, comfort, safety and efficiency of the built environment by integrating people, place, process and technology, as defined by the International Organization for Standardization (ISO). The profession is certified through Global Facility Management Association (Global FM) member organizations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Facility_ID">Facility ID</a></td>
      <td>The facility ID number, also called a FIN or facility identifier, is a unique integer number of one to six digits, assigned by the U.S. Federal Communications Commission (FCC) Media Bureau to each broadcast station in the FCC Consolidated Database System (CDBS) and Licensing and Management System (LMS) databases, among others.\nBecause CDBS includes information about foreign stations which are notified to the U.S. under the terms of international frequency coordination agreements, FINs are also assigned to affected foreign stations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Facility_location">Facility location</a></td>
      <td>The study of facility location problems (FLP), also known as location analysis, is a branch of operations research and computational geometry concerned with the optimal placement of facilities to minimize transportation costs while considering factors like avoiding placing hazardous materials near housing, and competitors' facilities. The techniques also apply to cluster analysis.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Federal_Reserve">Federal Reserve</a></td>
      <td>The Federal Reserve System (also known as the Federal Reserve or simply the Fed) is the central banking system of the United States of America. It was created on December 23, 1913, with the enactment of the Federal Reserve Act, after a series of financial panics (particularly the panic of 1907) led to the desire for central control of the monetary system in order to alleviate financial crises.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Telecommunications_facility">Telecommunications facility</a></td>
      <td>In telecommunications, a facility is defined by Federal Standard 1037C as:\n\nA fixed, mobile, or transportable structure, including (a) all installed electrical and electronic wiring, cabling, and equipment and (b) all supporting structures, such as utility, ground network, and electrical supporting structures.\nA network-provided service to users or the network operating administration.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>KINETIC CONCEPTS INC /TX/      ITEM 1A     RISK FACTORS       Risks Related to Our Business            We <font color="blue">face <font color="blue">significant</font></font> and <font color="blue">increasing competition <font color="blue">which could</font> <font color="blue">adversely</font></font>     affect our operating results</td>
    </tr>
    <tr>
      <td>Historically,  our  VAC  systems  have <font color="blue">competed primarily with</font>     <font color="blue">traditional wound care dressings</font>, other advanced wound care dressings, skin     substitutes, products containing growth factors and other <font color="blue">medical devices</font>     used for wound care</td>
    </tr>
    <tr>
      <td>As a result of the success of our VAC systems,     <font color="blue">competitors</font> have announced or <font color="blue">introduced products</font> similar to or designed to     mimic our VAC systems</td>
    </tr>
    <tr>
      <td>In this regard, BlueSky Medical Group, Inc</td>
    </tr>
    <tr>
      <td>is     marketing a pump and <font color="blue">dressing kits</font> to <font color="blue">compete directly with</font> VAC systems</td>
    </tr>
    <tr>
      <td>In 2004, BlueSky received US FDA clearance of its pump and one of its     dressings, which have <font color="blue">recently <font color="blue">been assigned</font> by</font> the <font color="blue">Centers for Medicare </font>and     Medicaid Services (“CMS”) to the <font color="blue"><font color="blue">reimbursement</font> codes</font> for Negative Pressure     Wound  Therapy,  the  same  codes  assigned  to our VAC systems and     <font color="blue">disposables</font></td>
    </tr>
    <tr>
      <td>Also, BlueSky <font color="blue">previously</font> announced that a large midwest     managed  care  <font color="blue">organization</font>  has implemented a <font color="blue">coverage policy</font> for its     product</td>
    </tr>
    <tr>
      <td>We believe the BlueSky device violates our <font color="blue">intellectual property</font>     rights and have <font color="blue">taken legal action against</font> BlueSky, its supplier and several     of its <font color="blue">distributors</font> to protect our rights</td>
    </tr>
    <tr>
      <td>While we have successfully     challenged the marketing of imitative VAC <font color="blue">systems by several</font> <font color="blue">European     </font>companies, we may not be successful in our challenge of BlueSky and may not     prevail in the <font color="blue">pending <font color="blue">litigation</font></font></td>
    </tr>
    <tr>
      <td>If these <font color="blue">competitors</font> or others are able     to legally develop and market their products or obtain Medicare or other     third-party <font color="blue">reimbursement</font> for <font color="blue">competing products</font>, our position in the wound     <font color="blue">care market could <font color="blue">substantially</font> erode</font> or our pricing of VAC <font color="blue">systems could</font>     decline <font color="blue"><font color="blue">significant</font>ly</font>, either of <font color="blue"><font color="blue">which could</font> <font color="blue">materially</font></font> and <font color="blue"><font color="blue">adversely</font> affect</font>     our  operating  results</td>
    </tr>
    <tr>
      <td>We  derived  dlra706dtta0  million in revenue, or     approximately 58prca of our <font color="blue">total revenue</font> for the year ended <font color="blue">December </font>31, 2005,     from our domestic VAC products relating to the <font color="blue"><font color="blue">patents at</font> issue</font></td>
    </tr>
    <tr>
      <td>US     VAC revenue was dlra562dtta6 million and dlra399dtta9 million for 2004 and 2003,     <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>In the US, our <font color="blue"><font color="blue">therapeutic</font> surfaces</font> business <font color="blue">primarily competes with</font>     the Hill-Rom Company and Sizewise Rentals and in Europe with Huntleigh     Healthcare and Pegasus Limited</td>
    </tr>
    <tr>
      <td>We face the risk that innovation by our     <font color="blue">competitors</font>  in  our <font color="blue">markets may</font> render our <font color="blue">products less desirable</font> or     obsolete or that our <font color="blue">competitors</font> may <font color="blue">effectively</font> limit our <font color="blue">market access</font>     <font color="blue">through sole source contracts with</font> GPOs, large <font color="blue"><font color="blue">health care</font> providers</font> or     third-party payers, which also would <font color="blue"><font color="blue">adversely</font> affect</font> our operating results</td>
    </tr>
    <tr>
      <td>Our <font color="blue">intellectual property</font> is very important to our <font color="blue">competitive position</font>,     <font color="blue">especially</font> for our VAC products</td>
    </tr>
    <tr>
      <td>If we are <font color="blue">unsuccessful</font> in protecting and     maintaining our <font color="blue">intellectual property</font>, <font color="blue">particularly</font> our <font color="blue">rights under</font> the     <font color="blue">Wake Forest </font>patents, our <font color="blue">competitive position</font> would be harmed</td>
    </tr>
    <tr>
      <td>We invest substantial resources and place considerable <font color="blue">importance on</font>     obtaining and maintaining <font color="blue">patent protection</font> for our products, <font color="blue">particularly</font>,     our license <font color="blue">rights under</font> the <font color="blue">Wake Forest </font><font color="blue">patents on which</font> we rely in our     VAC business</td>
    </tr>
    <tr>
      <td>We have <font color="blue">numerous patents on</font> our <font color="blue">existing products</font> and     processes, and we <font color="blue">file applications as <font color="blue">appropriate</font></font> for <font color="blue">patents covering new</font>     <font color="blue"><font color="blue">technologies</font> as</font> they are developed</td>
    </tr>
    <tr>
      <td>However, the patents we own, or in which     we have rights, may not be <font color="blue">sufficiently broad</font> to protect our <font color="blue">technology</font>     position against <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>Issued patents owned by us, or licensed to us,     may be challenged, invalidated or <font color="blue">circumvented</font>, or the <font color="blue">rights granted under</font>     <font color="blue">issued patents may</font> not <font color="blue">provide us with competitive advantages</font></td>
    </tr>
    <tr>
      <td>We incur     substantial costs and diversion of <font color="blue"><font color="blue">management</font> resources</font> when we have to     assert or defend our <font color="blue">patent rights against others</font></td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue">third parties</font>     may claim that we are infringing their <font color="blue">intellectual property</font> rights, and we     may be found to infringe those <font color="blue">intellectual property</font> rights</td>
    </tr>
    <tr>
      <td>Any unfavorable     outcome in <font color="blue">intellectual property</font> disputes or <font color="blue"><font color="blue">litigation</font> could</font> cause us to     lose our <font color="blue">intellectual property</font> rights in <font color="blue">technology</font> that is material to our     business</td>
    </tr>
    <tr>
      <td>In addition, we may not be able to detect <font color="blue"><font color="blue">infringement</font> by third</font>     parties, and <font color="blue">could lose</font> our <font color="blue">competitive position</font> if we fail to do so</td>
    </tr>
    <tr>
      <td>In  2003, we filed a <font color="blue">lawsuit against</font> BlueSky Medical Group, Inc,     Medela, Inc, Medela AG and Patient Care Systems, Inc</td>
    </tr>
    <tr>
      <td>In the case, we     allege <font color="blue">infringement</font> of multiple claims under three VAC patents arising     from the <font color="blue">manufacturing</font> and marketing of a medical device by BlueSky</td>
    </tr>
    <tr>
      <td>We are     <font color="blue">seeking damages</font> and <font color="blue">injunctive relief</font> in the case</td>
    </tr>
    <tr>
      <td>Although it is not     possible to <font color="blue">reliably predict</font> the outcome of the BlueSky <font color="blue">litigation</font>, we     believe our claims are <font color="blue">meritorious</font></td>
    </tr>
    <tr>
      <td>However, we may be unable to obtain an     <font color="blue">injunction against</font> BlueSky, and we may not prevail in this <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>If     we  do not obtain an injunction or <font color="blue">otherwise prevail</font>, our share of the     advanced wound-care market for our VAC <font color="blue">system could</font> be <font color="blue"><font color="blue">significant</font>ly</font>     <font color="blue">reduced due</font> to <font color="blue">increased competition</font>, and pricing of VAC <font color="blue">systems could</font>     decline <font color="blue"><font color="blue">significant</font>ly</font>, either of <font color="blue"><font color="blue">which would</font> <font color="blue">materially</font></font> and <font color="blue"><font color="blue">adversely</font> affect</font>     our  operating  results</td>
    </tr>
    <tr>
      <td>In 1998, Mondomed NV and Paul Hartmann AG filed an opposition in     the <font color="blue">European Patent Office </font>to a <font color="blue">Wake Forest </font><font color="blue">European VAC </font>patent licensed     to KCI  In 2004, the <font color="blue">European Patent Office </font>issued a <font color="blue">decision upholding</font> the     patent</td>
    </tr>
    <tr>
      <td>The <font color="blue">decision corrected</font> the patent to expand the range of pressures     <font color="blue">covered by</font> the patent claims from 76 – 752 mmHg of <font color="blue">negative pressure</font> to 7dtta6     – 752 mmHg of <font color="blue">negative pressure</font> and modified the patent claims to provide     that the  &amp;quote screen means &amp;quote  <font color="blue">term describing</font> the dressing is an open-cell polymer     foam</td>
    </tr>
    <tr>
      <td>Our VAC <font color="blue">systems typically</font> operate between 50 and 200 mmHg of     <font color="blue">negative pressure</font>, with a <font color="blue">default setting</font> of 125 mmHg</td>
    </tr>
    <tr>
      <td>Mondomed NV <font color="blue">entered into</font> a     <font color="blue">settlement with us</font> and <font color="blue">withdrew from</font> the opposition</td>
    </tr>
    <tr>
      <td>The oral hearing for     the appeal is <font color="blue">currently set</font> for April 6, 2006</td>
    </tr>
    <tr>
      <td>In <font color="blue"><font color="blue">connection</font> with</font> the     hearing, the <font color="blue">Board of Appeals </font>advised the <font color="blue">parties on</font> a <font color="blue">preliminary</font> and     <font color="blue">nonbinding basis</font> that the range of pressures <font color="blue">covered by</font> the <font color="blue">patent should</font> be     changed to 103dtta8 – 752 mmHg</td>
    </tr>
    <tr>
      <td>If this <font color="blue">preliminary</font> ruling becomes final or     <font color="blue">Wake Forest </font>is not successful in its <font color="blue">appeal respecting</font> the <font color="blue">negative pressure</font>     ranges or the “screen means,” the patent claims could be narrowed or the     <font color="blue">patent could</font> be invalidated</td>
    </tr>
    <tr>
      <td>In either case, third-party <font color="blue">competitors</font> could     <font color="blue">gain market</font> share in Europe, <font color="blue"><font color="blue">which could</font> erode</font> our <font color="blue">market position</font> or cause     the  pricing of VAC systems to decline there, either of <font color="blue">which would</font>     <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affect</font> our operating results</td>
    </tr>
    <tr>
      <td>We derived dlra151dtta6     million in <font color="blue">revenue from</font> <font color="blue">European VAC </font>products, relating to the <font color="blue">patents at</font>     issue, or 12dtta5prca of our <font color="blue">total revenue</font> for the year ended <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>During the pendency of an appeal, the <font color="blue">original patents remain</font> in place</td>
    </tr>
    <tr>
      <td>We     do not believe that any decision in this <font color="blue">case will affect</font> US patents</td>
    </tr>
    <tr>
      <td>We expect similar <font color="blue">litigation</font> may arise in the future</td>
    </tr>
    <tr>
      <td>We also are     subject  to  product  <font color="blue">liability</font>  <font color="blue">litigation</font>  and risk arising from the     <font color="blue">manufacture</font> and marketing of our <font color="blue">medical products</font></td>
    </tr>
    <tr>
      <td>The costs of pursuing or     defending  this  <font color="blue">litigation</font> and other <font color="blue">litigation</font> that may arise may be     substantial</td>
    </tr>
    <tr>
      <td>Any <font color="blue">adverse determination</font> also could <font color="blue">materially</font> and <font color="blue">adversely</font>     affect our operating results</td>
    </tr>
    <tr>
      <td>We also have <font color="blue"><font color="blue">agreement</font>s</font> with <font color="blue">third parties</font>, including our exclusive     license <font color="blue">of the VAC </font><font color="blue">patents from</font> Wake Forest, that provide for licensing     of their patented or <font color="blue">proprietary <font color="blue">technologies</font></font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">agreement</font>s</font> include     royalty-bearing licenses</td>
    </tr>
    <tr>
      <td>If we were to lose the rights to license these     <font color="blue">technologies</font>, or our costs to license these <font color="blue">technologies</font> were to <font color="blue">materially</font>     increase, our business <font color="blue">would suffer</font></td>
    </tr>
    <tr>
      <td>Changes to third-party <font color="blue">reimbursement</font> policies could reduce the <font color="blue">reimbursement</font>     we receive for and <font color="blue"><font color="blue">adversely</font> affect</font> the demand for our products</td>
    </tr>
    <tr>
      <td>The demand for our products is <font color="blue">highly dependent on</font> the policies of     third-party payers such as Medicare, Medicaid, <font color="blue">private insurance</font> and managed     care  <font color="blue">organization</font>s  that  <font color="blue">reimburse us</font> for the sale and rental of our     products</td>
    </tr>
    <tr>
      <td>If coverage or <font color="blue">payment policies</font> of these third-party payers are     revised in light of <font color="blue">increased controls on <font color="blue">health care</font> spending</font> or otherwise,     the price we may charge or the demand for our <font color="blue">products may decrease</font></td>
    </tr>
    <tr>
      <td>In this regard, CMS from time to time publishes <font color="blue">reimbursement</font> policies     and rates that <font color="blue">may favorably</font> or <font color="blue">unfavorably affect</font> the <font color="blue">reimbursement</font> price     and market for our products</td>
    </tr>
    <tr>
      <td>In the past our VAC systems and <font color="blue">disposables</font>     have been the <font color="blue">only devices assigned</font> to the CMS <font color="blue"><font color="blue">reimbursement</font> codes</font> for     <font color="blue">Negative Pressure Wound Therapy</font></td>
    </tr>
    <tr>
      <td>CMS recently announced that a pump and     <font color="blue">dressing kits</font> marketed by BlueSky have <font color="blue">been assigned</font> to the same Negative     Pressure Wound Therapy <font color="blue">codes under</font> the Healthcare Common Procedure Coding     System</td>
    </tr>
    <tr>
      <td>Also,  the  unique existing code for <font color="blue">reimbursement</font> <font color="blue">of VAC     </font>disposable  <font color="blue">canisters</font>  was <font color="blue">eliminated effective</font> <font color="blue">December </font>31, 2005, and     <font color="blue">consequently</font>, we are required to bill <font color="blue">Medicare Part B for VAC </font><font color="blue">canisters</font>     under a more <font color="blue">generic existing code at</font> a lower <font color="blue">reimbursement</font> rate beginning     <font color="blue">January  </font>1,  2006</td>
    </tr>
    <tr>
      <td>As a result of these recent CMS <font color="blue">decisions</font>, we may     experience <font color="blue">increased competition</font> from BlueSky products in <font color="blue">future periods</font>,     and the pricing we receive from other third-party payers may be <font color="blue">negatively</font>     impacted, either of <font color="blue"><font color="blue">which could</font> <font color="blue">materially</font></font> and <font color="blue"><font color="blue">adversely</font> affect</font> our business     and operating results</td>
    </tr>
    <tr>
      <td>The <font color="blue">assignment</font> of CMS <font color="blue"><font color="blue">reimbursement</font> codes</font> to BlueSky products also     increases the likelihood that our VAC <font color="blue">products will</font> be subject to the     Medicare <font color="blue"><font color="blue">competitive bidding</font> process</font> in 2007 <font color="blue">which could</font> <font color="blue">negatively</font> impact     KCI’s pricing for products that are <font color="blue">reimbursed by</font> Medicare in the home care     setting</td>
    </tr>
    <tr>
      <td>Any <font color="blue">price declines</font> in the Medicare setting could <font color="blue">materially</font> and     <font color="blue"><font color="blue">adversely</font> affect</font> our business</td>
    </tr>
    <tr>
      <td><font color="blue">As of March </font>6, 2006, no proposed rules have     <font color="blue">been adopted</font> for the <font color="blue">implementation</font> of the <font color="blue"><font color="blue">competitive bidding</font> process</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">reimbursement</font> of our products is also subject to review by the     <font color="blue">medical <font color="blue">directors</font></font> of the four Durable Medical Equipment Regional Carriers     (“DMERCs”)</td>
    </tr>
    <tr>
      <td>The <font color="blue">medical <font color="blue">directors</font></font> have indicated that <font color="blue">policy interpretation</font>     for coverage and payment of <font color="blue">durable medical equipment</font> in the home will be     <font color="blue">handled separately by each</font> of the <font color="blue">four regional</font> DMERCs</td>
    </tr>
    <tr>
      <td>As a result, our     products in the <font color="blue">past at times</font> have not been and in the <font color="blue">future may</font> not be     reimbursed  <font color="blue">uniformly by each</font> of the <font color="blue">four regional</font> DMERCs, <font color="blue">which could</font>     <font color="blue"><font color="blue">adversely</font> affect</font> our business and <font color="blue">operations</font> in a particular DMERC region     or, in the event of an <font color="blue"><font color="blue">adverse determination</font> by</font> all of the DMERCs, in all     regions</td>
    </tr>
    <tr>
      <td>We currently have approximately dlra11dtta0 million in outstanding     <font color="blue">receivables</font>  from  CMS related to <font color="blue">Medicare VAC </font><font color="blue">placements</font> that have     <font color="blue">extended beyond four months</font> in the home that are being disputed and denied     by CMS as billed, as a result of DMERC <font color="blue">policy interpretation</font></td>
    </tr>
    <tr>
      <td>We are in the     process of submitting these <font color="blue">receivables</font> through the <font color="blue">administrative process</font>     <font color="blue">necessary</font> to obtain payment</td>
    </tr>
    <tr>
      <td>We may not be successful in collecting these     amounts,  and if we are not, our <font color="blue">revenue may suffer as</font> a result of our     <font color="blue">inability</font> to collect these claims and due to our <font color="blue">inability</font> to continue to     provide  the  services that are <font color="blue">represented by</font> these <font color="blue">disputed types</font> of     claims</td>
    </tr>
    <tr>
      <td>Revenue arising <font color="blue">from such disputed</font> claims represents less than 1prca     of <font color="blue">total revenue</font> for 2005</td>
    </tr>
    <tr>
      <td>Due to the increased scrutiny and publicity of <font color="blue">increasing <font color="blue">health care</font></font>     costs, we may be subject to <font color="blue">future <font color="blue">assessment</font>s</font> or <font color="blue">studies by</font> CMS, the FDA,     or other agencies, <font color="blue">which could</font> lead to other changes in their <font color="blue">reimbursement</font>     policies that <font color="blue"><font color="blue">adversely</font> affect</font> our business</td>
    </tr>
    <tr>
      <td>In this regard, we were     informed  in  <font color="blue">November  </font>2004 that CMS intends to evaluate the clinical     efficacy, functionality and <font color="blue">relative cost</font> <font color="blue">of the VAC </font>system and a variety     of other <font color="blue">medical devices</font> to determine whether they should be included in a     <font color="blue"><font color="blue">competitive bidding</font> process</font></td>
    </tr>
    <tr>
      <td>A negative <font color="blue">assessment</font> with respect to the     efficacy of the VAC, or one that is perceived to be negative, could     <font color="blue"><font color="blue">adversely</font> affect</font> the <font color="blue">reimbursement</font> of, or demand for, the <font color="blue">VAC            </font>More recently, we have <font color="blue">learned from</font> the 2006 work plan of the Office of     the Inspector General (“OIG”) that the OIG plans to conduct a study on     <font color="blue">Negative Pressure Wound Therapy</font> during 2006</td>
    </tr>
    <tr>
      <td>The OIG Office of Evaluations     and Inspections <font color="blue">evaluates <font color="blue">effectiveness</font></font> and <font color="blue">efficiency</font> of a wide range of     programs  of  the  <font color="blue">Department  </font>of  <font color="blue">Health and Human Services</font></td>
    </tr>
    <tr>
      <td>We have     <font color="blue">participated</font> in similar studies in the past on other <font color="blue">product lines</font></td>
    </tr>
    <tr>
      <td>As part     of the <font color="blue">current study</font>, the OIG has <font color="blue">requested copies</font> of our <font color="blue">billing records</font>     for <font color="blue">Medicare VAC </font><font color="blue">placements</font></td>
    </tr>
    <tr>
      <td>KCI submitted all <font color="blue">copies as requested</font> and     plans to <font color="blue">cooperate fully with</font> any and all <font color="blue">future requests associated with</font>     these <font color="blue">evaluations</font></td>
    </tr>
    <tr>
      <td>In the event we are unable to <font color="blue">satisfactorily</font> meet the     <font color="blue">requirements</font> of the OIG in <font color="blue"><font color="blue">connection</font> with</font> this study, our prior billings     could  be  subject  to claims audits, <font color="blue">which could</font> result in demands by     third-party payers for refunds or <font color="blue">recoupments</font> of amounts <font color="blue">previously</font> paid to     us</td>
    </tr>
    <tr>
      <td>The results of this <font color="blue">study could also</font> factor <font color="blue">into determinations</font> of the     <font color="blue">inherent reasonableness</font> of our VAC pricing, and to what extent our VAC     <font color="blue">therapy will</font> be subject to the <font color="blue"><font color="blue">competitive bidding</font> process</font></td>
    </tr>
    <tr>
      <td>If  we are unable to develop <font color="blue">new generations</font> of VAC and <font color="blue">therapeutic</font>     <font color="blue">surface products</font> and <font color="blue">enhancements</font> to <font color="blue">existing products</font>, we <font color="blue">may lose market</font>     share as our existing patent rights begin to expire over time</td>
    </tr>
    <tr>
      <td>Our success is <font color="blue">dependent upon</font> the successful development, introduction     and <font color="blue">commercialization</font> of <font color="blue">new generations</font> of products and <font color="blue">enhancements</font> to     existing  products</td>
    </tr>
    <tr>
      <td><font color="blue">Innovation </font>in developing new <font color="blue">product lines</font> and in     developing <font color="blue">enhancements</font> to our existing VAC and <font color="blue"><font color="blue">therapeutic</font> surfaces</font>     products is required for us to grow and compete <font color="blue">effectively</font></td>
    </tr>
    <tr>
      <td>Over time, our     <font color="blue">existing foreign</font> and domestic <font color="blue">patent protection</font> in both the VAC and     <font color="blue"><font color="blue">therapeutic</font> surfaces</font> <font color="blue">businesses</font> will begin to expire, <font color="blue">which could</font> allow     <font color="blue">competitors</font> to adopt our older unprotected <font color="blue">technology</font> into competing product     lines</td>
    </tr>
    <tr>
      <td>If  we  are  unable to continue developing <font color="blue">proprietary product</font>     <font color="blue">enhancements</font>  to VAC systems and <font color="blue"><font color="blue">therapeutic</font> surfaces</font> products that     <font color="blue">effectively</font> make <font color="blue">older products obsolete</font>, we <font color="blue">may lose market</font> share in our     <font color="blue">existing lines</font> of business</td>
    </tr>
    <tr>
      <td>In addition, if we fail to develop new lines of     products,  we will not be able to <font color="blue">penetrate new markets</font></td>
    </tr>
    <tr>
      <td><font color="blue">Innovation </font>in     <font color="blue">enhancements</font> and new products requires <font color="blue">significant</font> capital <font color="blue">commitments</font> and     <font color="blue">investments</font> on our part, which we may be unable to recover</td>
    </tr>
    <tr>
      <td>If our future operating results do not meet our <font color="blue">expectations</font> or those of the     <font color="blue">equity research <font color="blue">analysts covering us</font></font>, the <font color="blue">trading price</font> of our <font color="blue">common stock</font>     <font color="blue">could fall dramatically</font></td>
    </tr>
    <tr>
      <td>We have experienced and expect to continue to experience <font color="blue">fluctuations</font>     in revenue and earnings for a number of reasons, including:            -  the level of <font color="blue">acceptance</font> of our VAC <font color="blue">systems by customers</font> and     physicians;          -  the type of <font color="blue">indications</font> that are <font color="blue">appropriate</font> for VAC use and the     <font color="blue">percentages</font> of wounds that are good             <font color="blue">candidates</font> for VAC Therapy;          -  <font color="blue">clinical studies</font> that may be published regarding the efficacy of     VAC Therapy, including <font color="blue">studies published</font>             by our <font color="blue">competitors</font> in an effort to challenge the efficacy of the     VAC;          -  <font color="blue">developments</font> or any <font color="blue">adverse determination</font> in our <font color="blue">pending <font color="blue">litigation</font></font>;          -   third-party <font color="blue">government</font> or private <font color="blue">reimbursement</font> policies with     respect to VAC treatment and competing             products; and          -  new or <font color="blue">enhanced competition</font> in our <font color="blue">primary markets</font></td>
    </tr>
    <tr>
      <td>We believe that the <font color="blue">trading price</font> of our <font color="blue">common stock</font> is based, among     other factors, on our expected rates of growth in revenue and <font color="blue">earnings per</font>     share</td>
    </tr>
    <tr>
      <td>If  we  are unable to realize <font color="blue">growth rates consistent with</font> our     <font color="blue">expectations</font>  or those of the <font color="blue">analysts covering us</font>, we would expect to     realize a decline in the <font color="blue">trading price</font> of our stock</td>
    </tr>
    <tr>
      <td>Historically, VAC     <font color="blue">revenue growth</font> has <font color="blue">been somewhat seasonal with</font> a slowdown in VAC rentals     beginning in the <font color="blue">fourth quarter</font> and <font color="blue">continuing into</font> the first quarter, which     we believe is caused by year-end clinical treatment patterns</td>
    </tr>
    <tr>
      <td>The adverse     effects in our business arising <font color="blue">from seasonality may become</font> more pronounced     in <font color="blue">future periods</font> as the market for the VAC <font color="blue">systems matures</font> and VAC     <font color="blue">growth rates decrease</font></td>
    </tr>
    <tr>
      <td>Because our staffing and operating expenses are <font color="blue">based on</font> anticipated     revenue levels, and because a <font color="blue">high percentage</font> of our costs are fixed, even     small <font color="blue">decreases</font> in revenue or delays in the <font color="blue">recognition</font> of <font color="blue">revenue could</font>     cause  <font color="blue">significant</font> variations in our operating results <font color="blue">from quarter</font> to     quarter</td>
    </tr>
    <tr>
      <td>In the short term, we do not have the ability to adjust spending in     a time-effective manner to compensate for any <font color="blue">unexpected revenue shortfall</font>,     <font color="blue">which also could</font> cause a <font color="blue">significant</font> decline in the <font color="blue">trading price</font> of our     stock</td>
    </tr>
    <tr>
      <td>Failure of any of our randomized and <font color="blue">controlled studies</font> or a third-party     study or <font color="blue">assessment</font> to <font color="blue">demonstrate</font> VAC therapyapstas clinical efficacy may     <font color="blue">reduce physician usage</font> of VAC and cause our VAC revenue to decline</td>
    </tr>
    <tr>
      <td>For  the  past several years, we have been conducting a number of     <font color="blue">clinical studies</font> designed to test the efficacy of VAC <font color="blue">across targeted</font>     <font color="blue">wound types</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">successful <font color="blue">clinical trial program</font></font> is <font color="blue">necessary</font> to maintain     and  increase  sales of VAC products, in addition to supporting and     maintaining third-party <font color="blue">reimbursement</font> of the product in the <font color="blue"><font color="blue">United States </font>    </font>and abroad, <font color="blue">particularly</font> in Europe, Canada and Japan</td>
    </tr>
    <tr>
      <td>If a clinical trial     <font color="blue">conducted by</font> us or others fails to <font color="blue">demonstrate</font> <font color="blue">statistically</font> <font color="blue">significant</font>     results supporting the efficacy or cost <font color="blue">effectiveness</font> of VAC therapy,     <font color="blue">physicians may elect</font> not to use VAC <font color="blue">therapy as</font> a treatment in general, or     for the type of wound in question</td>
    </tr>
    <tr>
      <td>Furthermore, in the event of an adverse     clinical  trial,  VAC  therapy  may  not achieve “standard-of-care”     <font color="blue">designations</font> for the <font color="blue">wound types</font> in question, <font color="blue">which could</font> deter the adoption     of VAC in those <font color="blue">wound types</font> or others</td>
    </tr>
    <tr>
      <td>If we are unable to develop a     body of <font color="blue">statistically</font> <font color="blue">significant</font> evidence from our <font color="blue">clinical trial program</font>,     whether  due  to adverse results or the <font color="blue">inability</font> to complete properly     designed studies, domestic and <font color="blue">international public</font> and <font color="blue">private payers could</font>     refuse to cover VAC therapy, limit the manner in which they cover VAC     therapy, or reduce the price they are willing to pay or reimburse for VAC     therapy</td>
    </tr>
    <tr>
      <td>We  may  be  subject to claims audits that <font color="blue">could harm</font> our business and     financial results</td>
    </tr>
    <tr>
      <td>As a <font color="blue">health care</font> supplier, we are subject to extensive <font color="blue">government</font>     regulation, including laws regulating <font color="blue">reimbursement</font> under various <font color="blue">government</font>     programs</td>
    </tr>
    <tr>
      <td>The billing, <font color="blue">documentation</font> and other practices of <font color="blue">health care</font>     suppliers  are subject to scrutiny, including claims audits</td>
    </tr>
    <tr>
      <td>To ensure     <font color="blue">compliance with</font> Medicare <font color="blue">regulations</font>, contractors, such as the DMERCs, which     serve as the <font color="blue">government</font>apstas agents for the processing of claims for products     sold for home use, periodically conduct audits and <font color="blue">request medical records</font>     and  other  <font color="blue">documents</font> to support claims <font color="blue">submitted by us</font> for payment of     services rendered to our customers</td>
    </tr>
    <tr>
      <td>Because we are a DME supplier, those     <font color="blue">audits involving home use</font> include review of patient claims records</td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font>audits can result in delays in obtaining <font color="blue">reimbursement</font> and denials of claims     for  payment <font color="blue">submitted by us</font></td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">government</font> could demand     <font color="blue">significant</font> refunds or <font color="blue">recoupments</font> of <font color="blue">amounts paid by</font> the <font color="blue">government</font> for     claims which are determined by the <font color="blue">government</font> to be <font color="blue">inadequately supported</font>     by the required <font color="blue">documentation</font></td>
    </tr>
    <tr>
      <td>More recently, we have <font color="blue">learned from</font> the 2006 work plan of the Office of     the Inspector General (“OIG”) that the OIG plans to conduct a study on     <font color="blue">Negative Pressure Wound Therapy</font> during 2006</td>
    </tr>
    <tr>
      <td>In  addition, private payers may also conduct audits, such as one     <font color="blue">conducted by</font> <font color="blue">Michigan Blue Cross</font></td>
    </tr>
    <tr>
      <td>We reviewed a <font color="blue">preliminary</font> report of their     findings and filed a response in <font color="blue">December </font>2004 and are <font color="blue">currently negotiating</font>     on  specific  claims</td>
    </tr>
    <tr>
      <td>Although no abusive or <font color="blue">fraudulent</font> practices were     identified by the payer, it is unclear what refunds or <font color="blue">recoupments</font> will be     expected <font color="blue">based on</font> claims reviews</td>
    </tr>
    <tr>
      <td>KCI will have <font color="blue">appeal rights with</font> regard to     any <font color="blue">such determinations</font></td>
    </tr>
    <tr>
      <td>Because we <font color="blue">depend upon</font> a limited group of suppliers and, in some cases,     <font color="blue">exclusive suppliers</font> for <font color="blue">products essential</font> to our business, we may incur     <font color="blue">significant</font> product development costs and experience material delivery     delays if we lose any <font color="blue">significant</font> supplier, <font color="blue"><font color="blue">which could</font> <font color="blue">materially</font></font> impact     our rental and sales of VAC systems and <font color="blue">disposables</font></td>
    </tr>
    <tr>
      <td>We obtain some of our finished products and <font color="blue">components from</font> a limited     group of suppliers</td>
    </tr>
    <tr>
      <td>In particular, we <font color="blue">rely exclusively on</font> Avail Medical     Products, Inc</td>
    </tr>
    <tr>
      <td>for the <font color="blue">manufacture</font> and packaging of our VAC <font color="blue">disposables</font></td>
    </tr>
    <tr>
      <td>VAC therapy cannot be <font color="blue">administered without</font> the <font color="blue">appropriate</font> use of our     VAC units in <font color="blue">conjunction with</font> the related VAC <font color="blue">disposables</font></td>
    </tr>
    <tr>
      <td>Total     VAC rental and sales revenue represented approximately 75prca of our total     revenue  for  2005,  of  <font color="blue">which sales</font> of VAC <font color="blue">disposables</font> represented     approximately 23prca</td>
    </tr>
    <tr>
      <td>Accordingly, a shortage of VAC <font color="blue">disposables</font> would     <font color="blue">inevitably</font> cause our revenue to decline and, if material or continued, may     also reduce our <font color="blue">market position</font></td>
    </tr>
    <tr>
      <td>We have a long-term evergreen supply <font color="blue">agreement</font> with Avail through     October  2008, which automatically extends for additional twelve-month     periods in October of each year, unless either party gives notice to the     contrary</td>
    </tr>
    <tr>
      <td>We require Avail to maintain duplicate <font color="blue">manufacturing</font> <font color="blue">facilities</font>,     tooling and raw material resources for the production of our <font color="blue">disposables</font> in     <font color="blue">different locations</font> to decrease the risk of <font color="blue">supply interruptions from</font> any     single Avail <font color="blue">manufacturing</font> <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>However, should Avail or Avail’s     suppliers  fail  to perform in <font color="blue">accordance with</font> their <font color="blue">agreement</font> and our     <font color="blue">expectations</font>, our supply of VAC <font color="blue">disposables</font> could be <font color="blue">jeopardize</font>d, which     could  <font color="blue">negatively</font>  impact  our VAC revenue</td>
    </tr>
    <tr>
      <td>The terms of the supply     <font color="blue">agreement</font> provide that <font color="blue">key indicators</font> be provided to us that <font color="blue">would alert us</font>     to  Availapstas  <font color="blue">inability</font>  to perform under the <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>We maintain an     inventory  of  <font color="blue">disposables</font>  sufficient  to  support  our  business for     <font color="blue">approximately six weeks</font> in the <font color="blue">United States </font>and eight weeks in Europe</td>
    </tr>
    <tr>
      <td>However, in the event that we are unable to replace a shortfall in supply,     our <font color="blue">revenue could</font> be <font color="blue">negatively</font> impacted in the short term</td>
    </tr>
    <tr>
      <td>Avail <font color="blue">relies exclusively on</font> Foamex International, Inc</td>
    </tr>
    <tr>
      <td>for the supply     of foam used in the VAC <font color="blue">disposable dressings</font></td>
    </tr>
    <tr>
      <td>While in <font color="blue">bankruptcy</font>, Foamex could     breach or terminate its <font color="blue">purchase orders with</font> Avail, reject, delay or refuse     to fulfill Avail orders, cease production of the foam <font color="blue">necessary</font> for our     VAC products, or <font color="blue">sell production</font> to a <font color="blue">third party</font></td>
    </tr>
    <tr>
      <td>Any of these outcomes     could <font color="blue">jeopardize</font> Avail’s supply of foam and hence our supply <font color="blue">of VAC     </font><font color="blue">disposables</font></td>
    </tr>
    <tr>
      <td>We are in the process of identifying other suppliers that     <font color="blue">could provide such inventory</font> to meet our needs in the event that Foamex is     unable  to  do so</td>
    </tr>
    <tr>
      <td>If we are required but unable to <font color="blue">timely procure</font> an     <font color="blue">alternate source</font> for this foam at an <font color="blue">appropriate</font> cost, our ability to obtain     the raw material resources required for our VAC <font color="blue">disposables</font> could be     compromised, <font color="blue">which would</font> have a <font color="blue">materially</font> adverse effect on our entire     VAC business</td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">numerous laws</font> and <font color="blue"><font color="blue">regulations</font> governing</font> the <font color="blue">health care</font>     industry, and non-<font color="blue">compliance with</font> such laws, as well as changes in such laws     or <font color="blue">future interpretations</font> of such laws, could reduce demand for and limit     our  ability  to  distribute  our products and could cause us to incur     <font color="blue">significant</font> compliance costs</td>
    </tr>
    <tr>
      <td>There are <font color="blue">widespread <font color="blue">legislative efforts</font></font> to control <font color="blue">health care</font> costs     in  the <font color="blue">United States </font>and abroad, which we expect will continue in the     future</td>
    </tr>
    <tr>
      <td>Recent publicity has <font color="blue">highlighted</font> the need to control <font color="blue">health care</font>     <font color="blue">spending at</font> the federal (Medicare) and state (Medicaid) levels</td>
    </tr>
    <tr>
      <td>We believe     this <font color="blue">pressure will intensify over</font> time</td>
    </tr>
    <tr>
      <td>For example, the <font color="blue">enactment</font> of the     <font color="blue">Medicare Modernization Act </font><font color="blue">eliminated annual payment increases on</font> the VAC     system  for the <font color="blue">foreseeable future</font> and initiated a <font color="blue">competitive bidding</font>     program</td>
    </tr>
    <tr>
      <td>At this time, we are unable to determine whether and to what extent     these changes would be applied to our products and our business but this or     similar <font color="blue">legislative efforts</font> in the future could <font color="blue">negatively</font> impact demand for     our products</td>
    </tr>
    <tr>
      <td><font color="blue">Substantially </font>all of our products are subject to <font color="blue">regulation by</font> the FDA     and its foreign <font color="blue">counterparts</font></td>
    </tr>
    <tr>
      <td><font color="blue">Complying </font>with FDA <font color="blue">requirements</font> and other     applicable  <font color="blue">regulations</font>  imposes <font color="blue">significant</font> costs and <font color="blue">expenses on</font> our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we fail to comply with applicable <font color="blue">regulations</font>, we could be     subject  to  <font color="blue">enforcement</font>  sanctions,  our <font color="blue">promotional practices may</font> be     restricted,  and  our  <font color="blue">marketed products could</font> be subject to recall or     otherwise  impacted</td>
    </tr>
    <tr>
      <td>In addition, new FDA guidance and new and amended     <font color="blue">regulations</font> that regulate the way we do business <font color="blue">may occasionally</font> result in     <font color="blue">increased compliance costs</font></td>
    </tr>
    <tr>
      <td>Recently, the FDA published notice of its intent     to implement new dimensional <font color="blue">requirements</font> for <font color="blue">hospital bed</font> side rails that     may require us to change the size of openings in new side rails for some of     our <font color="blue">surface products</font></td>
    </tr>
    <tr>
      <td>Over time, related <font color="blue">market demands might also</font> require     us to <font color="blue">retrofit products</font> in our <font color="blue">existing rental fleet</font>, and more extensive     <font color="blue">product modifications might</font> be required if FDA decides to <font color="blue">eliminate certain</font>     <font color="blue">exemptions</font> in their <font color="blue">proposed guidelines</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font><font color="blue">authorities</font> in Europe     and Canada have <font color="blue">also recently adopted</font> the revised standard, IEC 60601,     requiring labeling and electro-magnetic compatibility modifications to     several <font color="blue">product lines</font> in order for them to remain state-of-the-art</td>
    </tr>
    <tr>
      <td><font color="blue">Listing     </font>bodies in the US are expected to adopt similar <font color="blue">revised standards</font> in 2010</td>
    </tr>
    <tr>
      <td>Each of these <font color="blue">revised standards</font> will entail increased costs relating to     <font color="blue">compliance with</font> the new <font color="blue">mandatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>We are also subject to <font color="blue">various federal</font> and state <font color="blue">laws pertaining</font> to     <font color="blue">health care</font> fraud and abuse, including <font color="blue">prohibitions on</font> the submission of     false  claims  and  the  payment  or  <font color="blue">acceptance</font> of kickbacks or other     <font color="blue">remuneration</font> in return for the purchase or lease of our products</td>
    </tr>
    <tr>
      <td>The United     States Department of Justice and the Office of the Inspector General of the     <font color="blue">United States </font>Department of <font color="blue">Health and Human Services</font> have launched an     <font color="blue">enforcement</font> initiative which specifically targets the long-term care, home     health  and DME <font color="blue">industries</font></td>
    </tr>
    <tr>
      <td><font color="blue">Sanctions </font>for violating these laws include     criminal penalties and civil sanctions, including fines and penalties, and     possible exclusion from the Medicare, Medicaid and other federal <font color="blue">health care</font>     programs</td>
    </tr>
    <tr>
      <td>In  addition,  we  are  subject to <font color="blue">various environmental laws</font> and     <font color="blue">regulations</font> both within and outside the <font color="blue">United States </font><font color="blue">affecting</font> the use of     substances in our <font color="blue">manufacturing</font> and <font color="blue">sterilization processes</font></td>
    </tr>
    <tr>
      <td><font color="blue">Compliance     </font><font color="blue">with such laws</font> can entail substantial cost and any failure to <font color="blue">comply could</font>     result in substantial fines, penalties and delays in marketing the affected     products</td>
    </tr>
    <tr>
      <td>Risks Related to Our Capital Structure       Our substantial indebtedness could <font color="blue"><font color="blue">adversely</font> affect</font> our <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We have a <font color="blue">significant</font> amount of debt</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had     dlra295dtta9 million of <font color="blue">outstanding indebtedness</font> and <font color="blue">shareholders</font> &amp;apos  equity of     dlra191dtta5 million</td>
    </tr>
    <tr>
      <td>This  level  of  indebtedness  could  have  important     <font color="blue">consequences</font>, including the following:            -  it may be <font color="blue">difficult</font> for us to satisfy our <font color="blue"><font color="blue">obligations</font> under</font> our     senior credit <font color="blue">facility</font> and our <font color="blue">senior subordinated</font>             notes;          -  if we <font color="blue">default on</font> our <font color="blue">secured debt</font>, these <font color="blue">lenders may <font color="blue">foreclose on</font></font>     our assets;          -   we  may have to use a <font color="blue">significant</font> amount of our <font color="blue">cash flow</font> for     <font color="blue">scheduled debt service rather than</font> for <font color="blue">operations</font>;          -  we may be less able to obtain other debt or <font color="blue">equity financing</font> in the     future;          -  we could be less able to take advantage of <font color="blue">significant</font> business     <font color="blue">opportunities</font>, including <font color="blue">acquisitions</font> or             <font color="blue">divestitures</font>; or          -   our  <font color="blue">vulnerability</font>  to  <font color="blue">general adverse economic</font> and industry     <font color="blue">conditions could</font> be increased; and we could be at             a <font color="blue">competitive disadvantage compared</font> to <font color="blue">competitors</font> with less debt</td>
    </tr>
    <tr>
      <td><font color="blue">Restrictive  </font>covenants in our senior credit <font color="blue">facility</font> and the indenture     governing our <font color="blue">senior subordinated</font> notes <font color="blue">may restrict</font> our ability to pursue     our business strategies</td>
    </tr>
    <tr>
      <td>Our senior credit <font color="blue">facility</font> and the <font color="blue">indenture governing</font> our senior     subordinated notes limit our ability, among other things, to:            -  <font color="blue">incur additional indebtedness</font> or <font color="blue">contingent <font color="blue">obligations</font></font>;          -  <font color="blue">pay dividends</font> or make <font color="blue">distributions</font> to our <font color="blue">shareholders</font>;          -  repurchase or redeem our stock;          -  make <font color="blue">investments</font>;          -  <font color="blue">grant liens</font>;          -  make <font color="blue">capital expenditures</font>;          -  <font color="blue">enter into transactions with</font> our <font color="blue">shareholders</font> and <font color="blue">affiliates</font>;          -  <font color="blue">sell assets</font>; and          -   acquire  the  assets  of, or merge or <font color="blue">consolidate with</font>, other     companies</td>
    </tr>
    <tr>
      <td>Our senior credit <font color="blue">facility</font> contains financial covenants requiring us to     <font color="blue">meet certain leverage</font> and <font color="blue">interest coverage ratios</font></td>
    </tr>
    <tr>
      <td>Specifically, we are     obligated not to <font color="blue">permit ratios</font> to <font color="blue">fall outside certain specified ranges</font> and     maintain <font color="blue">minimum levels</font> of EBITDA            We may not be able to maintain these ratios</td>
    </tr>
    <tr>
      <td><font color="blue">Covenants </font>in our senior     credit <font color="blue">facility</font> may also impair our ability to finance future <font color="blue">operations</font> or     capital needs, or to enter into <font color="blue">acquisitions</font> or <font color="blue">joint ventures</font> or engage in     other favorable business <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">default under</font> our senior credit <font color="blue">facility</font>, we could be prohibited     from making any <font color="blue">payments on</font> our <font color="blue">senior subordinated</font> notes</td>
    </tr>
    <tr>
      <td>In addition, the     <font color="blue">lenders under</font> our senior credit <font color="blue">facility</font> could require <font color="blue">immediate repayment</font>     of the <font color="blue">entire principal then outstanding</font></td>
    </tr>
    <tr>
      <td>If those lenders require immediate     repayment,  we may not be able to repay them and <font color="blue">also repay</font> our senior     subordinated notes in full</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">generate sufficient cash</font>     flow or otherwise obtain funds <font color="blue">necessary</font> to make required <font color="blue">payments under</font> our     senior credit <font color="blue">facility</font>, or if we are unable to maintain the <font color="blue">financial ratios</font>     under our senior credit <font color="blue">facility</font>, we will be in <font color="blue">default under</font> our senior     credit <font color="blue">facility</font>, <font color="blue">which could</font>, in turn, cause a <font color="blue">default under</font> our senior     subordinated notes, the related indenture and any other <font color="blue">debt <font color="blue">obligations</font></font>     that we <font color="blue">may incur from</font> time to time</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">obligations</font>  under  our  senior  credit  <font color="blue">facility</font>  are <font color="blue">secured by</font>     <font color="blue">substantially</font> all of our assets</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">obligations</font> under</font> our senior credit <font color="blue">facility</font> are <font color="blue">secured by</font> liens     on <font color="blue">substantially</font> all of our assets, and the <font color="blue">guarantees</font> of certain of our     <font color="blue">subsidiaries</font>  under our senior credit <font color="blue">facility</font> are <font color="blue">secured by</font> liens on     <font color="blue">substantially</font> all of such <font color="blue">subsidiaries</font> &amp;apos  assets</td>
    </tr>
    <tr>
      <td>If we become insolvent or     are liquidated, or if <font color="blue">payment under</font> our senior credit <font color="blue">facility</font> or of other     secured <font color="blue">obligations</font> are <font color="blue">accelerated</font>, the <font color="blue">lenders under</font> our senior credit     <font color="blue">facility</font> or the <font color="blue">obligees with respect</font> to the other secured <font color="blue">obligations</font> will     be entitled to exercise the <font color="blue">remedies available</font> to a <font color="blue">secured lender under</font>     <font color="blue">applicable law</font> and the applicable <font color="blue"><font color="blue">agreement</font>s</font> and <font color="blue">instruments</font>, including the     right to <font color="blue">foreclose on</font> all of our assets</td>
    </tr>
    <tr>
      <td>Our articles of <font color="blue">incorporation</font>, our by-laws and Texas <font color="blue">law contain provisions</font>     that could discourage, delay or prevent a change in control or <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Our  articles  of <font color="blue">incorporation</font> and by-laws and Texas law contain     provisions <font color="blue">which could</font> discourage, delay or prevent a <font color="blue">third party</font> from     acquiring shares of our <font color="blue">common stock</font> or <font color="blue">replacing members</font> of our Board of     Directors</td>
    </tr>
    <tr>
      <td>These provisions include:              -  <font color="blue">authorization</font> of the issuance of <font color="blue">preferred stock</font>, the terms of which     may be determined at the <font color="blue">sole discretion</font> of the             Board of Directors;          -  <font color="blue">establishment</font> of a classified <font color="blue">Board of Directors </font><font color="blue">with staggered</font>,     three-year terms;          -  <font color="blue">provisions giving</font> the <font color="blue">Board of Directors </font>sole power to set the     number of <font color="blue">directors</font>;          -  <font color="blue">limitations</font> on the ability of <font color="blue">shareholders</font> to remove <font color="blue">directors</font>;          -  <font color="blue">requirements</font> for the approval of the holders of <font color="blue">at least two thirds</font>     of our outstanding <font color="blue">common stock</font> to amend our             articles of <font color="blue">incorporation</font>;          -  <font color="blue">authorization</font> for our <font color="blue">Board of Directors </font>to adopt, amend or repeal     our by-laws;          -  <font color="blue">limitations</font> on the ability of <font color="blue">shareholders</font> to call <font color="blue">special meeting</font>s     of <font color="blue">shareholders</font>; and          -  <font color="blue">establishment</font> of advance notice <font color="blue">requirements</font> for <font color="blue">presentation</font> of new     business and <font color="blue">nominations</font> for election to the             <font color="blue">Board of Directors </font><font color="blue">at shareholder meetings</font></td>
    </tr>
    <tr>
      <td>In addition, under Texas law and our articles of <font color="blue">incorporation</font> and our     by-laws, action may not be <font color="blue">taken by less than unanimous written consent</font> of     our <font color="blue">shareholders</font> unless the <font color="blue">Board of Directors </font>has recommended that the     <font color="blue">shareholders</font>  approve  such  action</td>
    </tr>
    <tr>
      <td>The <font color="blue">limitation on</font> the ability of     <font color="blue">shareholders</font> to call a <font color="blue">special meeting</font>, to act <font color="blue">by written consent</font> and to     remove <font color="blue">directors</font> may make it <font color="blue">difficult</font> for <font color="blue">shareholders</font> to remove or replace     the <font color="blue">Board of Directors </font>should they desire to do so</td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions could</font>     <font color="blue">also delay</font> or prevent a <font color="blue">third party</font> from acquiring us, <font color="blue">which could</font> cause the     <font color="blue">market price</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
  </tbody>
</table>